Scientists at Children?s Hospital of Pittsburgh of UPMC have identified a protein that is critical to the development of inflammation during lung infection in patients with cystic fibrosis (CF). The identification of this protein, called interleukin-23 (IL-23), is an important finding that gives researchers a specific target for developing new therapies.
The clinical difference is small, but the evidence is in ? waltzing does more than other aerobic exercise (ET) for the health of a patient with chronic heart failure (CHF).
Researchers are taking cardiac devices already in the operating room and using them in radically different applications as extracorporeal life support systems in cardiac arrest or traumatic hemorrhage.
Dancing improves ability to function and quality of life among chronic heart failure patients and may be a good alternative to other aerobic exercises, researchers reported at the American Heart Association’s Scientific Sessions 2006.
A diagnosis of breast cancer has taken on a new meaning in the past 10 years, as research has produced a host of new therapies and detection techniques, significantly improving long-term survival for women who have been fighting the disease.
Data presented at this year’s American College of Rheumatology Congress (ACR) show that patients receiving repeat treatment with MabThera/Rituxan (rituximab) achieved continued improvement in both physical and mental aspects of quality of life measures. In addition, a higher proportion of patients achieved a significant improvement in disease symptoms with a second course of MabThera, compared to the first course they received.
Venom from a West Indian tarantula has been shown to cause pain by exciting the same nerve cells in mice that sense high temperatures and the hot, spicy ingredient in chili peppers, UCSF scientists have discovered.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ORENCIA? (abatacept) in adult patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate and TNF antagonists. The data also demonstrate that ORENCIA provided clinically meaningful improvements in multiple aspects of health-related quality of life and physical function, sustained improvements in pain and had a consistent safety and tolerability profile through two years of treatment. These data will be presented at the upcoming 2006 American College of Rheumatology (ACR) Annual Scientific Meeting.
Researchers at the University of Virginia School of Medicine and Federal University of Cear? in Brazil have joined forces to study if the gene believed to contribute to Alzheimer’s protects children from the developmental stresses of early childhood diarrhea.
Researchers have identified a novel biomarker for brain tumors and have uncovered a potential role the marker may play when the tumor spreads or comes back after treatment. The biomarker, a protein known as “soluble attractin,” is normally absent in the central nervous system and is undetectable in cerebral spinal fluid unless malignant astrocytomas are present in the CNS. This newfound ability to identify biomarkers for malignant astrocytomas means physicians will have a minimally invasive method to track the success of treatments.